Figure 7.
Meta-analysis of Artesunate + Amodiaquine (AS+AQ) Versus Arthemeter-Lumefantrine (AL) according to country.
All studies that satisfied the inclusion criteria were included in this analysis. The outcome measure of interest (day 28 parasitological failure) is not clinically desirable; therefore, the right side of the graph favours Arthemeter-Lumefantrine.